CW-15337

N/A

Report date: 2023/03/12 17:11:06
NME

Base Information

Drug NameCW-15337
Drug Alias NameCW-15337
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complex
Therapy Area/IndicationsMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBrighton and Sussex Medical School
China Registration ClassN/A

Develop Information

Active CompaniesBrighton and Sussex Medical School
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A